<DOC>
	<DOCNO>NCT02895100</DOCNO>
	<brief_summary>The main objective study evaluate efficacy , safety , tolerability daily dose PTG-100 subject moderate severe ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Safety Efficacy Study PTG-100 Treatment Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>This Phase II multi-center , double blind , randomize , placebo-controlled , clinical study evaluate efficacy , safety , tolerability oral peptide , PTG-100 , administer capsule 12 week subject moderate severe UC . Following screening procedure confirmation subject eligibility , subject randomize 1:1:1:1 one three daily dose PTG-100 ( 150 , 300 900 mg ) placebo . Stratification base subject ' prior treatment anti-TNF agent , maximum 50 % subject prior unsuccessful anti-TNF agent treatment . Subjects treat study drug 12 week . Sigmoidoscopies perform Screening Visit Week 12 . A final Follow Up Visit occur Week 16 , subject study treatment 4 week . Clinical , safety , pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter evaluate ongoing basis 16 week study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Inclusion Criteria include : Male female subject age 18 80 year , inclusive Diagnosis UC least 2 month prior screen Moderate severe active UC define Mayo Score 6 12 inclusive ( range 012 ) baseline endoscopy score least 2 ( range 03 ) Subject must inadequate response , loss response intolerance least following medication : immunomodulators , TNFalpha antagonists corticosteroid Subject unlikely conceive , define one following : ) subject male , b ) subject surgically sterilize female , c ) subject postmenopausal female &gt; = 45 year age clinical documentation menopause , ) subject woman child bear potential ( WOCBP ) agree abstain heterosexual activity , use adequate hormonal contraception use double barrier contraception . For WOCBP , negative pregnancy test screening within 24 hour first dose study medication Exclusion Criteria include : Subject Crohn 's Disease ( CD ) , indeterminate colitis ( IC ) presence history fistula CD History toxic megacolon , abdominal abscess , symptomatic colonic stricture stoma ; history imminent risk colectomy History current evidence colonic dysplasia adenomatous colonic polyp Current bacterial parasitic pathogenic enteric infection , include Clostridium difficile , infection hepatitis B C virus , infection human immunodeficiency virus , infection require hospitalisation intravenous antimicrobial therapy , opportunistic infection within 6 month , infection require antimicrobial therapy within 2 week , history one episode herpes zoster episode disseminate zoster Live virus vaccination within one month prior screen Subject concurrent clinically significant , unstable , uncontrolled cardiovascular , pulmonary , hepatic , renal , gastrointestinal , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , medical disorder , opinion investigator , might confound study result pose additional risk subject Known primary secondary immunodeficiency History myocardial infarction , unstable angina , transient ischaemic attack , decompensated heart failure require hospitalisation , congestive heart failure ( NYHA Class 3 4 ) , uncontrolled arrhythmia , cardiac revascularisation , stroke , uncontrolled hypertension , uncontrolled diabetes within 6 month screen Clinically meaningful laboratory abnormality screen Pregnant lactate female Any surgical procedure require general anaesthesia within one month prior screening , plan elective surgery study History malignant neoplasm carcinoma situ within 5 year prior screen History major neurological disorder , judge Investigator , positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist Current recent history alcohol dependence illicit drug use within 1 year prior screen . Subject mentally legally incapacitated time screen visit history clinically significant psychiatric disorder would impact subject 's ability participate trial accord investigator Unable attend study visit comply procedure Concurrent participation interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>inflammatory bowel disease</keyword>
</DOC>